A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery

BACKGROUND: Predicting treatment response or survival of cancer patients remains challenging in immuno-oncology. Efforts to overcome these challenges focus, among others, on the discovery of new biomarkers. Despite advances in cellular and molecular approaches, only a limited number of candidate bio...

Descripción completa

Detalles Bibliográficos
Autores principales: Creemers, Jeroen H A, Lesterhuis, W Joost, Mehra, Niven, Gerritsen, Winald R, Figdor, Carl G, de Vries, I Jolanda M, Textor, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169479/
https://www.ncbi.nlm.nih.gov/pubmed/34059522
http://dx.doi.org/10.1136/jitc-2020-002032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169479/
https://www.ncbi.nlm.nih.gov/pubmed/34059522
http://dx.doi.org/10.1136/jitc-2020-002032

Ejemplares similares